Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
106 hedge funds and large institutions have $33.5M invested in Accelerate Diagnostics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 12 closing their positions.
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1% less funds holding
Funds holding: 107 → 106 (-1)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
73% less capital invested
Capital invested by funds: $125M → $33.5M (-$91.2M)
94% less call options, than puts
Call options by funds: $18K | Put options by funds: $284K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$1.4M |
| 2 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$665K |
| 3 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
+$554K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$506K |
| 5 |
State Street
Boston,
Massachusetts
|
+$401K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$2.55M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.77M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.36M |
| 4 |
Axa
Paris,
France
|
-$1.23M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$524K |
AXDX Hedge Fund Activity: Q1 2022 in Review
106 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2022, worth a combined $33.5M — down 73% from $125M a quarter earlier.
Fund positioning in AXDX was balanced in Q1 2022: 12 funds opened new positions, 12 closed out, 30 added to existing stakes and 33 trimmed.
The largest buyer was Griffin Asset Management, adding an estimated $1.4M. The largest seller was Oracle Investment Management, cutting an estimated $2.55M.
- 106 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2022, down from 107 in Q4 2021.
- Funds reported $33.5M of Accelerate Diagnostics stock for Q1 2022, down 73% quarter-over-quarter.
- 12 funds opened new Accelerate Diagnostics positions in Q1 2022 and 12 closed out, a net change of 0 holders.
- The largest Accelerate Diagnostics buyer in Q1 2022 was Griffin Asset Management, an estimated $1.4M added.
- The largest Accelerate Diagnostics seller in Q1 2022 was Oracle Investment Management, an estimated $2.55M sold.
Based on aggregated 13F filings for Q1 2022.